Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Tejara Capital Ltd

Tejara Capital Ltd lowered its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 12.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,661,547 shares of the biotechnology company’s stock after selling 644,269 shares during the quarter. Heron Therapeutics accounts for about 4.6% of Tejara Capital Ltd’s investment portfolio, making the stock its 8th biggest holding. Tejara Capital Ltd’s holdings in Heron Therapeutics were worth $7,132,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Anfield Capital Management LLC boosted its holdings in shares of Heron Therapeutics by 5.6% in the fourth quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 6,264 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Heron Therapeutics by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company’s stock valued at $1,692,000 after buying an additional 9,418 shares during the period. Glenmede Trust Co. NA boosted its holdings in shares of Heron Therapeutics by 49.6% in the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 10,578 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Heron Therapeutics by 10.6% in the fourth quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 10,909 shares during the period. Finally, Zacks Investment Management boosted its holdings in shares of Heron Therapeutics by 2.4% in the third quarter. Zacks Investment Management now owns 475,575 shares of the biotechnology company’s stock valued at $946,000 after buying an additional 11,320 shares during the period. Institutional investors and hedge funds own 80.01% of the company’s stock.

Analyst Upgrades and Downgrades

HRTX has been the subject of several research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price target on shares of Heron Therapeutics in a report on Friday, February 28th. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 8th.

Heron Therapeutics Trading Up 3.0 %

Shares of HRTX opened at $2.39 on Tuesday. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The firm has a fifty day simple moving average of $1.86 and a 200 day simple moving average of $1.74. The stock has a market capitalization of $364.07 million, a price-to-earnings ratio of -13.28 and a beta of 1.55.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.05. The business had revenue of $40.78 million for the quarter, compared to analyst estimates of $37.37 million. As a group, research analysts predict that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.